Interactions of transforming growth factor-β and angiotensin II in renal fibrosis

Hypertension

Volumn 31, Issue 1 II SUPPL., 1998, Pages 181-188

  Border, Wayne A ^a   Noble, Nancy A ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Angiotensin II; Fibrosis; Kidney; Transforming growth factor

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; TRANSFORMING GROWTH FACTOR BETA; ANGIOTENSIN II; INTEGRIN;

ANIMAL CELL; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; FIBROGENESIS; GLOMERULONEPHRITIS; HYPERTENSION; KIDNEY DISEASE; KIDNEY FIBROSIS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; BIOSYNTHESIS; FIBROSIS; GENE TRANSFER; HUMAN; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANGIOTENSIN II; ANIMALS; FIBROSIS; GENE TRANSFER TECHNIQUES; HUMANS; INTEGRINS; KIDNEY; KIDNEY DISEASES; PLASMIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031601718     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.31.1.181     Document Type: Conference Paper

References (83)

1. Esther CR Jr, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MR, Bernstein KE. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest. 1997;99: 2375-2385.
2. Lee Y-A, Liang C-S, Lee M-A, Lindpaintner K. Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: A comprehensive study of all its components in the dog. Proc Natl Acad Sci U S A. 1996;93:11035-11040.
3. Sporn MB. The importance of context in cytokine action. Kidney Int. 1997;51:1352-1354.
4. Rosenberg ME, Smith LJ, Correa Rotter R, Hostetter TH. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int. 1994; 45:403-410.
5. Matsusaka T, Hymes J, Ichikawa I. Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol. 1996;7:2025-2043.
6. Fogo A, Kon V. Treatment of hypertension. Semin Nephrol. 1996;16: 555-566.
7. Border WA, Noble NA. Transforming growth factor-β in tissue fibrosis. N Engl J Med. 1994;331:1286-1292.
8. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest. 1994;93:2431-2437.
9. Noble NA, Border WA. Angiotensin II in renal fibrosis: should TGF-β rather than blood pressure be the therapeutic target? Semin Nephrol. 1997; 17:455-466.
10. Border WA, Noble NA. TGF-β. Sci Am Sci Med. 1995;2:68-77.
11. Border WA, Ruoslahti E. Transforming growth factor-β: the dark side of tissue repair. J Clin Invest. 1992;90:107.
12. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS. Hepatic expression of mature transforming growth factor b1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A. 1995;92:2572-2576.
13. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Böttinger EP, Klotman PE, Thorgeirsson SS. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab Invest. 1996;74: 991-1003.
14. Border WA, Noble NA. TGF-β in kidney fibrosis: a target for gene therapy. Kidney Int. 1997;51:1388-1396.
15. Ohno M, Cooke JP, Dzau VJ, Gibbons GH. Fluid shear stress induces endothelial transforming growth factor-β1 transcription and production. J Clin Invest. 1997;95:1363-1369.
16. Lee L, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest. 1995;96: 953-964.
17. Tamaki K, Okuda S, Nakayama M, Yanagida T, Fujishima M. Transforming growth factor-β1 in hypertensive renal injury in Dahl salt-sensitive rats. J Am Soc Nephrol 1996;7:2578-2589.
18. Horikoshi S, McCune BK, Ray PE, Kopp JB, Sporn MB, Klotman PE. Water deprivation stimulates transforming growth factor-β2 accumulation in the juxtaglomerular apparatus of mouse kidney. J Clin Invest. 1992;88: 2117-2122.
19. Ray PE, McCune BK, Gomez RA, Horikoshi S, Kopp JB, Klotman PE. Renal vascular induction of TGF-β2 and renin by potassium depletion. Kidney Int. 1993;44:1006-1013.
20. Ray PE, McCune B, Gomez RA, Ruley EJ, Klotman PE. Expression of transforming growth factor b3 in hypertrophic juxtaglomerular apparatus. N Engl J Med. 1994;330:68-69.
21. Antonipillai I, Hoang Le T, Soceneantu L, Horton R. Transforming growth factor-β is a renin secretagogue at picomolar concentrations. Am J Physiol. 1993;265:F537-F541.
22. Ray PE, McCune BK, Geary KM, Carey RM, Klotman PE, Gomez RA. Modulation of renin release and renal vascular smooth muscle cell contractility by TGF-β2. Contrib Nephrol. 1996;118:238-248.
23. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest. 1996;98:1996-1970.
24. Kelly FJ, Thompson MM, Oyama TT, Ledbetter SR, Pratt BM, Anderson S. Recombinant human TGF-β2 in the volume depleted rat. J Am Soc Nephrol. 1997;8:603A. Abstract.
25. Feige J-J, Cochet C, Rainey WE, Mandani C, Chambaz EM. Type b transforming growth factor affects adrenocortical cell-differential functions. J Biol Chem. 1987;262:13491-13405.
26. Gupta P, Franco-Saenz R, Gentry LE, Mulrow PJ. Transforming growth factor b1 inhibits aldosterone and stimulates adrenal renin in cultured bovine zona glomerulosa cells. Endocrinology. 1992;131:631-636.
27. Husted RF, Matsushita K, Stokes JB. Induction of resistance to mineralocorticoid hormone in cultured inner medullary collecting duct cell by TGF-β1. Am J Physiol. 1994;267:F767-F775.
28. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063-1068.
29. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985;76:612-619.
30. Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985;313;1617-1620.
31. Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J. 1986;293:471-474.
32. Hommel E, Parving H-H, Mathiesen E, Edsberg B, Nielsen MD, Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J. 1986;293:467-470.
33. Insua A, Ribstein J, Mimran A. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Postgrad Med J. 1988;64(suppl 3):59-62.
34. Baba T, Murabayashi S, Takebe K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive (non-insulin dependent) diabetic patients with microalbuminuria: a randomized controlled trial. Diabetologia. 1989;32:40-44.
35. Bauer JH, Reams GP, Hewett J, Klachko D. A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis. 1992;20:443-457.
36. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J. 1992;304:339-343.
37. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
38. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis. 1994;23:247-254.
39. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-1650.
40. Parving H-H, Jacobsen P, Rossing K, Smidt UM, Hommel E, Rossing P. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int. 1996;49:1778-1782.
41. Lopes-Ovejero JA, Saal SDF, D'Angelo WA, Cheigh JS, Stengel KH, Laragh JH. Reversal of vascular and renal crisis of scleroderma by oral angiotensin-converting enzyme blockade. N Engl J Med. 1979;300: 1417-1419.
42. Herlitz H, Edeno C, Mulec H, Westberg G, Aurell M. Captopril treatment of hypertension and renal failure in systemic lupus erythematosis. Nephron. 1984;38:253-256.
43. De Venuto G, Andreotti C, Mattarei M, Pegoretti G. Prolonged treatment of essential hypertension and renal function: comparison of captopril and beta-blockers considering microproteinuria values. Curr Ther Res. 1985;38: 710-718.
44. Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med. 1992;326: 910-915.
45. Nishimura M, Okamura M, Konishi Y, Inoue K, Young CK, Yoshioka T, Negoro N, Inoue T, Kanayama Y. Effect of treatment with ACE inhibitor (ACEI) on TGF-β gene expressions in renal biopsy from patients with IgA nephropathy. J Am Soc Nephrol. 1995;6:397. Abstract.
46. Burns GC, Matute R, Onyema D, Davis I, Toth D. Response to inhibition of angiotensin converting enzyme in HIV-associated nephropathy. Am J Kidney Dis. 1994;23:441-443.
47. Burns GC, Paul SK, Sivak SL, Toth IR. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol. 1997;8:1140-1146.
48. Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis. 1996;28:202-208.
49. Wilson C, Byrom FB. The viscious circle in chronic Bright's disease: experimental evidence from the hypertensive rats. Q J Med. 1940;10: 65-96.
50. Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int. 1989;36: 626-635.
51. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int. 1992;42:46-55.
52. Junaid A, Rosenberg ME, Hostetter TH. Interaction of angiotensin II (AII) and transforming growth factor beta (TGF-β) in the remnant kidney. J Am Soc Nephrol. 1993;4:772. Abstract.
53. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 1994;24:195-204.
54. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H. Contribution of renal angiotensin II type 1 receptor to gene expressions in hypertension-induced renal injury. Kidney Int. 1994;46:1346-1358.
55. Ohta K, Kim S, Hamaguchi A, Yukimura T, Miura K, Takaori K, Iwao H. Role of angiotensin II in extracellular matrix and transforming growth factor-β1 expression in hypertensive rats. Eur J Pharmacol. 1994;269: 115-119.
56. Shankland SJ, Ly H, Thai K, Scholey JW. Increased glomerular capillary pressure alters glomerular cytokine expression. Circ Res. 1994;75:844-853.
57. Pimentel JL Jr, Sundell CL, Wang S, Kopp JB, Montero A, Martinez-Maldonado M. Role of angiotensin II in the expression and regulation of transforming growth factor-β in obstructive nephropathy. Kidney Int. 1995;48:1233-1246.
58. Ruiz-Ortega M, Gonzalez S, Seron D, Condom E, Bustos C, Largo R, Gonzalez E, Ortiz A, Egido J. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int. 1995;48:1778-1891.
59. Ishidoya S, Morrissey J, McCracken R, Klahr S. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int. 1996;49:1110-1119.
60. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy. Kidney Int. 1997;52:660-673.
61. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997;51: 164-172.
62. Zoja C, Donadelli R, Corna D, Testa D, Facchinetti D, Maffi R, Luzzana E, Colosio V, Bertani T, Remuzzi G. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis. 1997;29:254-264.
63. Peters H, Border WA, Noble NA. Therapeutic reduction of TGF-β and matrix proteins in thy 1-induced glomerulonephritis is enhance by angiotensin blockade at higher doses and further enhanced by addition of low protein diet. J Am Soc Nephrol. 1997;8:524A. Abstract.
64. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol. 1992;140:95-107.
65. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. J Clin Invest. 1992;90:456-461.
66. Saksela O, Rifkin DB. Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol. 1988;4:93-126.
67. Baricos WH, Cortez SL, el Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int. 1995;47:1039-1047.
68. Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int. 1992;42:1462-1469.
69. Loskutoff DJ, Sawdey M, Keeton M, Schneiderman J. Regulation of PAI-1 gene expression in vivo. Thromb Haemost. 1993;70:135-137.
70. Feng L, Tang WW, Loskutoff DJ, Wilson CB. Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis. J Am Soc Nephrol. 1993;3:1753-1764.
71. Rondeau E, Mougenot B, Lacave R, Peraldi MN, Kruithof EKO, Sraer JD. Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. Clin Nephrol 1990;33:55-60.
72. Shihab FS, Yamamoto T, Nast CC, Cohen AH, Noble NA, Gold LI, Border WA. Transforming growth factor-β and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol. 1995;6:286-294.
73. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA. Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int. 1996;49:461-469.
74. Border WA, Yamamoto T, Noble NA, Gold L, Nast CC, Cohen AH. HIV-associated nephropathy is linked to TGF-β and matrix protein expression in human kidney. J Am Soc Nephrol. 1993;4:675. Abstract.
75. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin. Invest. 1996;97:232-237.
76. Olson JA Jr, Shiverick KT, Ogilvie S, Buhi WC, Raizada MK. Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Proc Natl Acad Sci U S A. 1991;88:1928-1932.
77. Rydzewski B, Zelezna B, Tang W, Sumners C, Raizada MK. Angiotensin II stimulation of plasminogen activator inhibitor-1 gene expression in astroglial cells from the brain. Endocrinology. 1992;130:1255-1262.
78. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and-2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995;95:1353-1362.
79. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest. 1995;95:995-1001.
80. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble NA. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int. 1997;51:646-671.
81. Romer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Dano K. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med. 1996;2:287-292.
82. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 1997;99:200-208.
83. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer J-D. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int. 1996;50:1897-1903.